ArticleJournal of clinical virology plus2023
High SARS-CoV-2 seroprevalence in Lagos, Nigeria with robust antibody and cellular immune responses.
Article in Journal of clinical virology plus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Reduced COVID-19 severity in Africa: a systematic review of host genetic and immunological responses to SARS-CoV-2 infection.Frontiers in immunology · 2026Pooled it
- Seroprevalence of endemic and emergent coronaviruses among SARS-COV-2 patients and healthcare workers in Abidjan, Côte d'Ivoire.BMC infectious diseases · 2026Article
- Article
- Knowledge, awareness, and perception of healthcare professionals towards Long COVID in Nigeria.Frontiers in public health · 2026Article
- COVID19 Sero-epidemiology and vaccine uptake in two Southern Nigerian clinics.PLOS global public health · 2026Article
- Immunodominant structural proteins Gc and N drive T cell-mediated protection against La Crosse virus.iScience · 2025Article
- SARS-CoV-2 seroprevalence and COVID-19 vaccination coverage in two states of Nigeria from a population based household survey.Scientific reports · 2025Article
- Safety and immunogenicity of fractional COVID-19 vaccine doses in Nigerian adults: A randomized non-inferiority trial.Scientific reports · 2025Article
- Pre-pandemic cross-reactive antibody and cellular responses against SARS-CoV-2 among female sex workers in Dakar, Senegal.Frontiers in public health · 2025Article
- The Adaptive Immune Response againstViruses · 2024Review
- Serological survey in a university community after the fourth wave of COVID-19 in Senegal.PloS one · 2024Article
- Performance of SARS COV-2 IgG Anti-N as an Independent Marker of Exposure to SARS COV-2 in an Unvaccinated West African Population.The American journal of tropical medicine and hygiene · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Early evidence suggested that the impact of the COVID-19 pandemic was less severe in Africa compared to other parts of the world. However, more recent studies indicate higher SARS-CoV-2 infection and COVID-19 mortality rates on the continent than previously documented. Research is needed to better understand SARS-CoV-2 infection and immunity in Africa. Methods: In early 2021, we studied the immune responses in healthcare workers (HCWs) at Lagos University Teaching Hospital ( Results: Antibody data demonstrated high SARS-CoV-2 seroprevalence of 72·4% (97/134) in HCWs and 60·3% (70/116) in the general population. Antibodies directed to only SARS-CoV-2 N, suggesting pre-existing coronavirus immunity, were seen in 9·7% (13/134) of HCWs and 15·5% (18/116) of the general population. T cell responses against SARS-CoV-2 N ( Conclusions: These results have important implications for understanding the paradoxically high SARS-CoV-2 infection with low mortality rate in Africa and supports the need to better understand the implications of SARS-CoV-2 cellular immunity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.